ADC |
directed antibody-drug conjugate |
AKT |
the serine/threonine protein kinase |
ALK |
Anaplastic lymphoma kinase |
APC |
antigen presenting cells |
ATF4 |
Activating Transcription Factor 4 |
BC |
breast cancer |
BL1 |
basal-like 1 |
BL2 |
basal-like 2 |
BRCA |
BReast CAncer gene |
CDK |
Cicline dependent kinase |
CI |
confidance interval |
CPS |
combined positive score |
ECM |
extracellular matrix |
EGFR |
Epidermal Growth Factor Receptor |
EMA |
European Medicine Agency |
ER |
estrogen receptor |
ETM |
epithelial to mesenchymal transition |
FAK |
focal adhesion kinase |
G-CSF |
Granulocyte Colony-Stimulating Factor |
GSIs |
γ -secretase inhibitors |
HER2 |
epidermal growth factor receptor-2 |
HIF1 |
Hypoxia-Inducible Factor |
HR |
hazard ratio |
IFN-γ |
Interferon gamma |
IGF-1R |
Insulin-like growth factor 1 |
IM |
immunomodulatory |
JAK |
Janus-family tyrosine kinase |
LAR |
luminal androgen receptor |
M |
mesenchymal-like |
MAPK |
Mitogen-activated protein kinase |
MDSCs |
suppressor cells of myeloid derived origin |
MET |
mesenchymal-epithelial transition factor |
MSL |
mesenchymal stem cell-like |
mTOR |
mammalian target of rapamycin |
MVA |
Modified Vaccinia Ankara |
NACT |
neoadjuvant chemotherapy |
NSCLC |
no small cell lung cancer |
ORR |
objective response rate |
OS |
overall survival |
PARP |
Poli ADP-ribose polymerase inhibitors |
pCR |
pathological complete response |
PD-1 |
programmed death-1 |
PDGF |
Platelet-Derived Growth Factor |
PD-L1 |
Programmed Death-Ligand 1 |
PFS |
progression free survival |
PI3K |
phosphatidylinositol-3-OH kinase |
PR |
progesterone receptor |
PTEN |
tensin homologue |
RTKs |
Receptor tyrosine kinases |
SFKs |
Src family kinases |
SH |
Src homology |
Src |
sarcoma oncogene cellular homolog |
STAT |
Signal transducer and activator of transcription |
TGF-β |
Tumor Necrosis Factor Beta |
TKI |
tyrosine kynase inhibitor |
TNBC |
triple negative breast cancer |
TP53 |
Tumor protein53 |
Trop-2 |
trophoblast cell surface antigen-2 |
VEGF |
vascular endothelial growth factors |